Triple negative breast cancers (TNBC) are a subtype of breast cancer characterized by negative expressions of estrogen receptor, progesterone receptor, and Her2/neu. Compared with other breast cancers, TNBC displays distinct clinic pathological features and prognosis, attracting much attention from oncology researchers. This review highlights the recent advances in the clinical characterization and treatment of TNBC.

Women diagnosed with breast cancer have a significantly higher risk of developing contralateral breast carcinoma.When the dignosis ofbilateral breast cancer (BBC)is established,the challenges for the doctors are to determine contralateral breast carcinoma is metastasis or primary lesions.The pathological type,receptor status,biological behavior and the prognosis of bilateral breast cancer are the issues have to be considered.On the other hand,we discuss which type of breast cancer trend to be bilateral breast cancer,thus more effective follow-up and preventive procedures would be applied on this part of patients to improve their quality of life and the curative rate.

Triple-negative breast cancer(TNBC)is a special subtype of breast cancer which is invalid to endocrine therapy.Anti-Her2 targeted therapies such as herceptin and lapatinib are not suitable to TNBC.At present,conventional chemotherapy is the only way for the medical therapy of TNBC.Thus,searching for novel therapeutic agents for TNBC is one of hot researches of breast cancer.New targeted therapy drugs such as PARP-1 inhibitors,EGFR inhibitors,CXCR4 inhibitors,anti-angiogenesis drugs,Src tyrosine kinase inhibitor,and mTOR inhibitor are being researched.

OBJECTIVE: To establish a CDDP-resistant cell line from human nasopharyngeal carcinoma and evaluate its biological characteristics. METHOD: By continuously exposing and gradually increasing dose of cisplatin (CDDP), a resistant nasopharyngeal carcinoma cell line (HNE1/CDDP) was established. Drug sensitivity of this cell line was detected by MTT assay; the alterations of its biological characteristics were determined using light microscopy, cell counting and flow cytometry (FCM); its ability of adhesion, migration and invasion were also evaluated. RESULT: HNE1/CDDP cell line was developed after 10 months with stable resistance to cisplatin with the resistance index was 5.83. HNE1/CDDP cell exhibited cross-resistance to many other chemotherapeutic agents (carboplatin, oxaliplatin and etoposide, etc). The morphology of HNE1/CDDP changed; doubling time prolonged; and the cell number of S-phase and G2/M-phase decreased while of G0/G1 phase increased compared with parental cells. The ability of adhesion, migration and invasion had no difference between the parental and the resistant cells. CONCLUSION HNE1/CDDP cell line shows the typical and stable resistant phenotype and can be used as a research model.
Antineoplastic Agents ; pharmacology ; Cell Line, Tumor ; Cisplatin ; pharmacology ; Drug Resistance, Multiple ; Drug Resistance, Neoplasm ; Humans ; Nasopharyngeal Neoplasms